Zydus Lifesciences has successfully acquired US-based Assertio Holdings Inc. for $166.4 million in a cash tender offer. This strategic move, completed through its subsidiary Zara Merger Sub Inc., makes Assertio a wholly-owned subsidiary and strengthens Zydus’s pipeline of innovative drugs, particularly in specialty and oncology supportive-care therapies.